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To examine the relationship between dialysis modality and prognosis in Japanese patients, we conducted a prospective multicenter
observational study. We recruited 83 background-matched peritoneal dialysis (PD) and 83 hemodialysis (HD) patients (average
age, 64.9 years; men, 53.6%; diabetic patients, 22.9%; median duration of dialysis, 48 months in all patients) and followed them
for 5 years. During the follow-up period, 27 PD patients (16 cardiovascular and 11 non-cardiovascular deaths) and 27 HD patients
died (14 cardiovascular and 13 non-cardiovascular deaths). There were 8 PD patients switched to HD, and 6 PD patients received
renal transplantation. Kaplan-Meier analysis revealed that the crude survival rate was not signiﬁcantly diﬀerent at the end of 5
years (PD 67.5% versus 67.5%, log-rank P = 0.719). The diﬀerence in cardiovascular and non-cardiovascular mortalities between
PD and HD was not statistically signiﬁcant. Multivariate Cox analysis showed that the independent predictors for death were age
and serum albumin levels, but not the dialysis modality. This studyshowed that the overall mortality was not signiﬁcantly diﬀerent
between PD and HD patients, which suggests that dialysis modality might not be an independent factor for survival in Japanese
patients.
1.Introduction
The number of end-stage renal disease patients requiring
renal replacement therapy is increasing worldwide. In Japan
peritoneal dialysis (PD) and hemodialysis (HD) are the two
major dialysis modalities. The prognosis associated with
these modalities is a clinically important issue and has been
debated for a long time.
Some studies show that PD is associated with a higher
mortality than HD [1, 2]. Other studies show that PD
patients have a higher survival rate than HD patients [3,
4]. Comprehensive analysis, including the results of large-
scale and prospective studies, revealed that the HD and PD
patients have a similar overall survival [5–7]. Another report
indicated that the survival rates of PD and HD patients
varied greatly depending on the characteristics of patients
and observational period [8].
In Japan, only a few studies have been performed on this
issue. A single-center study showed that the 3-year survival
of PD patients was higher than that of the background-
unmatched HD patients [9]. To clarify the diﬀerence in
mortality between PD and HD patients, we performed a2 International Journal of Nephrology
multicenter and background-matched analysis in Japanese
dialysis patients.
2.SubjectsandMethods
2.1. Patients. In our prospective cohort study, we recruited
clinical parameter-matched 83 PD and 83 HD patients on
maintenance dialysis from 6 hospitals in Yamagata and
Miyagiprefectures,administrativedistrictswithapopulation
of 1.2 and 2.3 million, respectively, located in the northern
part of Japan. The main purpose of this study was to
analyze the factors related to survival in dialysis patients.
Patients were registered in 2003 and were followed up until
the end of 2008. The median follow-up period was 60
months. Baseline information was collected at entry, and
the information for the prognosis was collected at the end
of each year. Cardiovascular death was deﬁned as the death
due to coronary heart disease, heart failure and stroke, or
cardiac sudden death that occurred within 1h after the
onset of acute symptoms. Patients recruited in the study
gave written informed consent. This study was performed
according to the Declaration of Helsinki and was approved
by the institutional ethics committee.
2.2.StatisticalAnalysis. Themeansandproportions between
groups were compared using unpaired Student t-test and
chi-square tests, respectively. The Mann-Whitney U-test was
used to compare the non-parametric data. Survival curves
were estimated using the Kaplan-Meier method followed
by the log-rank test. To examine the independent eﬀect
of the clinical parameters on prognosis, Cox-proportional
hazard analysis was used with adjustment for potential
confounders. The patients that changed the dialysis modality
were censored at the time of changing the modality. Data are
expressed as mean ± SD or median (min-max) for data not
normally distributed. All statistical analyses were performed
using Stat View version 5 (SAS Institute Inc., Cary, NC,
USA). A signiﬁcant diﬀerence was deﬁned as P<0.05.
3. Results
3.1. Patient Characteristics and Follow-Up. The baseline
characteristics of the 166 patients, including 83 PD and
83 HD patients, were as follows: average age, 64.9 years;
men, 53.6% (n = 89); diabetic patients, 22.9% (n = 38);
median duration of dialysis, 48 months. The baseline clinical
parameters including, age, gender, duration of dialysis,
and the types of administered drugs were not signiﬁcantly
diﬀerent between the PD and HD patients (Table 1).
During the 5-year follow-up period, there were 27 deaths
inthePDgroup(16cardiovascularand11noncardiovascular
deaths), including deaths from congestive heart failure (n =
8), stroke (n = 5), and infection (n = 2). In HD group, there
were 27 deaths (14 cardiovascular and 13 noncardiovascular
deaths), including deaths from congestive heart failure (n =
6), ischemic heart disease (n = 3), and infection (n = 4).
There were 8 PD patients switched to HD, and 6 PD patients
received renal transplantation.
3.2.AssociationbetweenMortalityandDialysisModality. The
5-year mortality associated with PD and HD was compared
using Kaplan-Meier analysis. The survival rate was not
signiﬁcantly diﬀerent at the end of 5 years (PD 67.5% versus
67.5%, log-rank P = 0.719) (Figure 1).
Then, we examined the diﬀerence in cardiovascular and
noncardiovascular mortalities between PD and HD patients.
The proportion of cardiovascular deaths among total deaths
was not signiﬁcantly diﬀerent between PD and HD (59.3%
versus 51.2%, P = 0.584). The event-free curves of PD and
HD patients were almost identical, and event-free rate at the
endof5yearswasnotsigniﬁcantlydiﬀerentincardiovascular
deaths (log-rank P = 0.511) and noncardiovascular deaths
(log-rank P = 0.844) (Figure 2).
Next, we performed a Cox-proportional analysis to
examine the independent eﬀect of the dialysis modality
on survival (Table 2). The univariate model showed that
the factors associated with 5-year survival were age, past
history of cardiovascular disease, serum albumin level, and
triglycerides level but not the modality of dialysis. Multi-
variate analysis, including the factors signiﬁcant according
to univariate analysis and dialysis modality, showed that the
independent predictors of survival were age (per 10 years
increase, hazard ratio [HR], 1.89; 95% conﬁdence interval
[CI], 1.34–2.64; P<0.001) and serum albumin level (per
1SD increase, HR, 0.67; 95% CI, 0.49–0.91; P = 0.011),
and the modality of dialysis was not signiﬁcantly associated
with the outcome. Similarly, the modality of dialysis was not
associated with the cardiovascular and noncardiovascular
mortalities.
4. Discussion
In this prospective multicenter study, we compared the 5-
year survival between background-matched HD and PD
patients. Our results showed no signiﬁcant diﬀerence in
all-cause, cardiovascular, and noncardiovascular mortalities
between HD and PD patients, which indicated that the
dialysis modality might not be an independent factor for the
survival in Japanese patients.
While many studies have compared the prognosis
between PD and HD, consistent results remain to be
obtained. One of the possible explanations is the diﬀerence
in the observational period. Although studies with observa-
tional periods within 3 years are likely to detect a diﬀerence
in survival between PD and HD patients [1, 3, 9], all the
studies with long observational periods (longer than 10
years) showed no diﬀerence in prognosis [6, 7, 10].
Another possibility is the diﬀerence in the characteristics
of participants. In Japan, PD is selected as renal replacement
therapy in less than 5% of incident patients, which is much
lower than that in other countries (10%–30% in most of
European and Asian countries, and 8% in the United States).
This suggests that there might be a bias in selecting the
dialysis modality in Japan. The selection bias could be a
confounding factor, and a proper adjustment for the back-
ground of subjects is indispensable for comparative analysis.
AlthoughapreviousJapanesereportshowedthatthesurvivalInternational Journal of Nephrology 3
Table 1: Baseline characteristics of patients.
Characteristics Peritoneal dialysis Hemodialysis P value
Number 83 83
Mean age (years) 63.9 ±12.76 5 .9 ±11.1 0.282
Men (%) 42.2 50.6 0.276
Duration of dialysis (months) 42 (5–310) 51 (9–305) 0.177
Body weight (kg) 55.5 ±6.15 2 .5 ±7.4 0.066
Obesity (%) 10.7 8.8 0.758
Diabetes (%) 18.1 27.7 0.139
Past history of CVD (%) 18.1 10.8 0.185
Systolic blood pressure (mmHg) 138 ±19 148 ±18 0.068
Diastolic blood pressure (mmHg) 75 ±10 76 ±10 0.891
Serum creatinine (mg/dL) 9.7 ±3.29 .4 ±2.3 0.644
Blood urea nitrogen (mg/dL) 54.0 ±12.25 7 .4 ±12.3 0.095
Albumin (g/dL) 3.5 ±0.43 .6 ±0.3 0.313
Hemoglobin (g/dL) 9.2 ±1.19 .7 ±0.9 0.069
Total cholesterol (mg/dL) 181 ±36 174 ±27 0.232
HDL cholesterol (mg/dL) 42.5 ±13.04 5 .9 ±15.5 0.251
Triglycerides (mg/dL) 147 ±76 131 ±106 0.401
Calcium (mg/dL) 9.2 ±1.09 .0 ±0.8 0.278
Phosphate (mg/dL) 5.1 ±1.35 .0 ±1.3 0.521
Intact PTH (mg/dL) 197 ±150 146 ±135 0.051
Use of phosphate binder (%) 92.3 84.1 0.446
Use of vitamin D analogs (%) 61.5 62.2 0.964
Use of ESA (%) 23.5 45.8 0.090
CVD: cardiovascular disease: HDL: high-density lipoprotein: PTH: parathyroid hormone: ESA: erythropoiesis-stimulating agents. Mean ± SD, Median (min-
max).
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Figure 1: Kaplan-Meier survival curves by dialysis modality. PD: peritoneal dialysis; HD: hemodialysis.4 International Journal of Nephrology
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Figure 2: Cardiovascular and noncardiovascular mortalities by dialysis modality. PD: peritoneal dialysis; HD: hemodialysis.
Table 2: Hazard ratios for clinical parameters derived by Cox proportional hazard analysis.
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age (per 10 years increase) 1.68 (1.33–2.13) <0.001 1.88 (1.34–2.64) <0.001
Past history of CVD (%) 2.42 (1.29–4.53) 0.006 1.75 (0.83–3.68) 0.141
Albumin level (per 1SD increase) 0.62 (0.48–0.81) <0.001 0.67 (0.49–0.91) 0.011
Triglycerides level (per 1SD increase) 0.60 (0.38–0.95) 0.029 0.73 (0.44–1.22) 0.232
Modality of dialysis (PD) 1.14 (0.65–1.88) 0.720 0.88 (0.44–1.74) 0.710
HR: hazard ratio: CI conﬁdence interval: SD: standard deviation: CVD: cardiovascular disease: PD: peritoneal dialysis.
was better in PD patients than in HD patients, the analysis
was performed without adjusting for the background of the
patients [9]. We performed an adjustment for the clinical
parameters, and our results showed that the diﬀerence in
survival rate was not signiﬁcant at the end of 5 years.
The discrepancy between our ﬁndings and those reported
previously may be because of the diﬀerence in analytical
methods, including the adjustment of background and the
follow-up period.
Previous studies have shown that age, comorbidities, and
nutritional parameters such as serum albumin level [11]
and/or total cholesterol levels are the factors related to the
prognosis in dialysis patients [12]. In the current study,
serumalbuminlevelwasanindependentpredictorfor5-year
survival. Our result is consistent with the previous ﬁnding
and suggests that the nutritional status is more important
than the dialysis modality in Japanese patients. Previously,
infection was the leading cause of death in PD patients.
However,theincidenceofinfectionwasdecreasedalongwith
recent advances in connecting devices.
Our study has advantages such as background-adjust-
ment and relatively long observational period; however,
there are several limitations to our study. First, we recruited
patientsundergoingdialysisnotincident patients.Therefore,
the dropout during the initial period of dialysis is not
examined in this study. Second, a daily variation is observed
in the clinical parameters. One time measurement of these
parameters might underestimate the association between the
parameters and the survival.
5. Conclusion
Thisbackground-matched5-yearobservationalstudyshowed
that all-cause, cardiovascular, and noncardiovascular mor-
talities were not signiﬁcantly diﬀerent between PD and HD
patients in Japan.
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